Enanta is advancing zelicapavir to Phase III trials after CMO Dr Scott Rottinghaus said it is justified by the Phase IIb data ...
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in ...
The Food and Drug Administration (FDA) has flagged a rare but potential link between the RSV vaccine—particularly Arexvy—and ...
Health experts are warning people about the 'tripledemic' threat as cases of flu, RSV and the new Covid variant Stratus are ...
The year 2023 marked the debut of groundbreaking innovations to prevent severe RSV infections in infants. Now protected ...
With the threat of a "tripledemic" looming, it's essential to be aware of the symptoms of the new Covid variant or know if ...
Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...
Enanta Pharmaceuticals said its experimental respiratory syncytial virus treatment significantly quickened recovery in a mid-stage study of adults at high risk of complications from the infection.
Susan Green developed a stubborn cough in December 2023. Nearly two years after contracting respiratory syncytial virus, or ...
Because there is no specific treatment for RSV, millions of parents would endure anxious days trying to clear mucus and ...
Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback